Core Viewpoint - JDE Peet's N.V. is involved in a recommended public offer by Keurig Dr Pepper, Inc. for all issued and outstanding shares of JDE Peet's, with the company announcing compliance with Dutch offer rules regarding share disclosures [1][3]. Group 1: Company Overview - JDE Peet's is recognized as the world's leading pure-play coffee company, operating in over 100 markets and focusing on brand-led growth through its key brands: Peet's, L'OR, and Jacobs [4]. - In 2025, JDE Peet's reported total sales of EUR 9.9 billion and employed more than 21,000 individuals globally [4]. Group 2: Share and Incentive Plans - The nominal value of each share in JDE Peet's is EUR 0.01, with the total issued share capital remaining unchanged at 488,178,642 shares, of which 3,144,957 are held as treasury shares [3]. - On March 23, 2026, the company granted 811,205 conditional rights to shares in the form of restricted stock units (RSUs) and performance stock units (PSUs) to 204 participants in its incentive plan [5]. - Additionally, JDE Peet's transferred 12,955 shares to 14 incentive plan participants, all for no consideration [5].

Group 1 - Ontex Group NV disclosed a significant shareholding notification indicating that Mr. Joannes G.H.M. Niessen and Mont Cervin SARL's voting rights fell below 3% of issued shares on March 23, 2026 [1] - The notification was received by Ontex on March 25, 2026, in compliance with Belgian law regarding the disclosure of significant shareholdings [1] Group 2 - Ontex is a leading international developer and producer of baby care, feminine care, and adult care products, primarily serving retailers and healthcare sectors in Europe and North America [3] - The company employs around 5,000 people and operates plants and offices in 12 countries, distributing innovative products in approximately 100 countries [3] - Ontex is headquartered in Aalst, Belgium, and is listed on Euronext Brussel [3]

Core Viewpoint - Falcon Oil & Gas Ltd. has provided an update on its transaction with Tamboran Resources Corporation, which has received shareholder approval and is now awaiting final court approval [2][3]. Group 1: Transaction Details - The transaction between Falcon and Tamboran was approved by shareholders on March 11, 2026, and is governed by an arrangement agreement dated September 30, 2025 [2]. - The Supreme Court of British Columbia approved the final order for the transaction on March 26, 2026, with certain amendments required for the treatment of Falcon shareholders subject to sanctions [3]. - Falcon and Tamboran are currently assessing the necessary amendments to the plan of arrangement and their implications for the transaction's implementation [4]. Group 2: Next Steps - The closing of the transaction is contingent upon meeting the conditions outlined in the arrangement agreement, and both companies plan to extend the outside date to allow more time for these conditions to be satisfied [4]. - Further updates regarding the transaction will be provided as they become available [4]. Group 3: Company Overview - Falcon Oil & Gas Ltd. is an international oil and gas company focused on the exploration and development of unconventional oil and gas assets, with operations in Australia, South Africa, and Hungary [8].

Core Viewpoint - Bavarian Nordic A/S has submitted clinical data to the European Medicines Agency (EMA) to extend the indication of the MVA-BN mpox and smallpox vaccine to include children aged 2 to 11 years, demonstrating a comparable safety profile and non-inferior immune response compared to adults [1][2]. Group 1: Clinical Study Results - The submission is based on positive topline results from a Phase 2 clinical study involving 227 children aged 2-11 years and 224 adults, showing non-inferiority of immune responses and a similar safety profile between both age groups after vaccination with two standard doses of the MVA-BN vaccine [2]. - The study was co-funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and conducted in the Democratic Republic of Congo and Uganda, where cases of mpox were reported during recent outbreaks [2]. Group 2: Implications and Statements - The potential extension of the Marketing Authorisation for MVA-BN to include individuals from 2 years of age could occur later in 2026 following EMA's review of the data [3]. - The President and CEO of Bavarian Nordic emphasized the importance of broadening vaccine access for children, who are disproportionately affected by mpox, especially in the context of ongoing health challenges [4]. - CEPI's Mpox Disease Programme Lead highlighted that children face a higher risk of severe disease during outbreaks, underscoring the need for expanded vaccine access for this vulnerable population [4]. Group 3: Vaccine Information - MVA-BN is the only non-replicating mpox vaccine approved in several countries, including the U.S., Switzerland, and the EU, originally developed as a smallpox vaccine to ensure supply for the entire population, including immunocompromised individuals [5]. - The vaccine is indicated for use in the general population from 12 years old for those considered at risk for smallpox or mpox infection [5]. Group 4: Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines and is a preferred supplier of mpox and smallpox vaccines to governments [6].

Group 1 - The Novaturas Group announced a change in its executive team, with Chief Financial Officer Auksė Kriaučiūnaitė stepping down as of March 27, and the company is currently searching for a new candidate [1][2] - The CEO of Novaturas, Ieva Galvydienė, expressed gratitude for Auksė's contributions during a dynamic period and wished her success in her future career [1] - The new CFO will oversee operations across Lithuania, Latvia, and Estonia, while internal resources will ensure CFO responsibilities during the selection process [2] Group 2 - Novaturas Group is a tour operator with over 25 years of experience, offering a wide range of travel destinations from the Baltic States [3] - In 2024, Novaturas Group recorded revenues of EUR 201 million and served 239 thousand passengers in Lithuania, Latvia, and Estonia [3]

Core Insights - DDPAI is expanding into the North American market by launching its products on Amazon Canada, aiming to enhance the mobility experience with affordable dashcam solutions [1][4] Market Context - Dashcams are increasingly essential for Canadian drivers due to the country's vast geography and challenging winter conditions, which can improve driving confidence and provide evidence in accidents [3] Product Offering - The DDPAI Z50 Pro features a 4K front and 1080P rear camera, enhanced night vision, and a supercapacitor for extreme weather, making it suitable for Canadian winters [7][8] - The Z50 Pro includes 24/7 Parking Monitoring, collision detection, and smart voice control, providing comprehensive safety features [9][11] - The N2 Dual model offers a compact design with 2.5K front recording and similar safety features, catering to different consumer preferences [10][13] Pricing and Promotions - The Z50 Pro is priced at CA$149.99 after a coupon, originally CA$179.99, while the N2 Dual is available for CA$99.99 after a coupon, originally CA$139.99, with the coupon valid until March 31, 2026 [14] Company Background - DDPAI was founded in 2013 and focuses on delivering high-quality dashcams through a streamlined manufacturing process, emphasizing quality control and user feedback [15][17]

Core Viewpoint - Arcadis has nominated Carl Trowell for appointment to its Supervisory Board for a four-year term, bringing extensive experience in energy and infrastructure management [1][4]. Group 1: Carl Trowell's Background - Carl Trowell currently serves as President of Strategic Infrastructure at National Grid PLC, overseeing a multi-billion pound portfolio of UK electricity transmission projects [2]. - He has a distinguished career with leadership roles at Acteon Group, ENSCO, and 17 years at Schlumberger, providing deep expertise in managing large-scale infrastructure and energy projects globally [3][8]. - Trowell has lived and worked internationally, including in the UK, Netherlands, Norway, France, and Malaysia, and has significant experience in leading major operations in the US and UK [3]. Group 2: Supervisory Board Changes - The Supervisory Board will submit a non-binding nomination for Trowell's appointment at the Annual General Meeting (AGM) on May 20, 2026, where he will join the Audit & Risk Committee and the Sustainability Committee [4]. - Michiel Lap will retire from the Supervisory Board after 11 years of service, with Peter de Wit succeeding him as Chair [5]. - Deanna Goodwin will also retire from the Supervisory Board, and Robert Swaak will take over her role as Chair of the Audit & Risk Committee [5]. Group 3: Strategic Importance - Michiel Lap expressed that Trowell's extensive experience in global power and energy organizations will provide valuable insights into managing large-scale capital projects, particularly those critical to the energy transition, which is a core focus for Arcadis [6].

Core Viewpoint - Bigbank AS is closing its Swedish branch, ceasing operations and selling its loan portfolio, with the closure process starting on 31 May 2026 [1] Group 1: Company Overview - Bigbank AS is a commercial bank with over 30 years of operating history, owned by Estonian capital [2] - As of 28 February 2026, the bank's total assets are 3.5 billion euros, with equity of 298 million euros [2] - The bank operates in nine countries, serving over 193,000 active customers and employing more than 650 people [2] - Moody's has assigned Bigbank a long-term bank deposit rating of Ba1, along with a baseline credit assessment (BCA) and an adjusted BCA of Ba2 [2] Group 2: Branch Closure Details - The Supervisory Board decided on 26 March 2026 to terminate the activities of the Swedish branch [1] - The bank will stop accepting deposits at the Swedish branch starting 27 March 2026, continuing to service only the existing deposit portfolio [1]

Core Viewpoint - Novartis is set to acquire Excellergy, Inc. to enhance its immunology strategy, particularly in food allergies and other IgE-driven diseases, with the lead asset Exl-111 showing promise in improving symptom control and convenience [1][2][3] Group 1: Acquisition Details - Novartis will pay up to USD 2 billion in upfront and milestone payments for the acquisition of Excellergy, with the transaction expected to close in the second half of 2026, pending regulatory approvals [4] Group 2: Product and Mechanism - Exl-111 is a half-life extended, high-affinity anti-IgE antibody currently in Phase 1, designed to dissociate receptor-bound IgE and achieve faster, deeper pathway suppression compared to conventional therapies [1][3] - The acquisition builds on Novartis's established expertise in IgE biology and aims to complement its existing allergy portfolio across various allergic conditions [2][3] Group 3: Strategic Importance - The proposed acquisition reflects Novartis's commitment to advancing innovative science to provide meaningful benefits to patients suffering from allergic diseases [3] - Exl-111 has the potential to support earlier symptom relief and broader use in conditions such as food allergies, chronic spontaneous urticaria, and allergic asthma, including pediatric populations [3]

Core Insights - IBA reported strong financial results for the fiscal year 2025, achieving record-high revenue and improved profitability, driven by robust commercial momentum in Proton Therapy and a historic order intake [1][2][6] Financial Performance - Total net sales increased by 24% to €620.2 million compared to €498.2 million in FY 2024 [3] - IBA Clinical segment saw a significant growth of 44% in net sales, reaching €395.3 million [3][4] - Gross profit rose to €199.6 million, a 19% increase from €168.1 million in the previous year, although gross margin slightly decreased to 32.2% from 33.7% [3][4] - Adjusted EBITDA surged by 54% to €49.4 million, with an adjusted EBITDA margin of 8.0% [3][4] - Net result increased by 38% to €12.7 million, resulting in earnings per share of €0.43 [3][4] Order Intake and Backlog - Equipment order intake reached a record €452 million, a 41% increase year-over-year, with IBA Clinical contributing significantly with an 81% growth [5] - The backlog hit an all-time high of €1.6 billion, providing strong visibility for future operations [5] Strategic Developments - The acquisition of ORA, a leader in radiochemistry, was completed, enhancing IBA's position in Nuclear Medicine [5][10] - The company successfully closed a €125 million bank refinancing package, strengthening its financial structure [10] Future Outlook - IBA set a Group Adjusted EBIT guidance of at least €32 million for FY 2026, building on the momentum from 2025 [10] - A dividend proposal of €0.25 per share is subject to approval at the Annual General Meeting [10]